Nilotinib Teva

Nilotinib, the active ingredient in Nilotinib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in patients who are in the chronic or accelerated phase. GNH USA supplies Nilotinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib is a targeted therapy used within the chronic myeloid leukemia (CML) disease pathway. - Chronic phase CML: reduces leukemic cell proliferation and helps achieve hematologic and cytogenetic remission. - Accelerated phase CML: provides disease control when the disease progresses beyond the chronic phase.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional upset stomach. - Diarrhea: loose stools, often transient. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusion or ischemia. - Pancreatitis: inflammation of the pancreas. - Severe hepatic impairment: marked liver dysfunction. - QT interval prolongation: potential cardiac rhythm disturbance.

Patients should be monitored for specific safety considerations while receiving Nilotinib. - Cardiac monitoring: assess for signs of arterial occlusive disease. - Liver function: check hepatic enzymes regularly. - Electrolytes: maintain potassium and magnesium within normal ranges to reduce QT risk. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Nilotinib can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nilotinib exposure. - Antacids containing aluminum or magnesium: can reduce absorption.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels. - Proton pump inhibitors: may modestly affect bioavailability.